Corbus Pharmaceuticals Holdings (CRBP) EBT Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly EBT Margin of 54130.64% for Q3 2021, down 4859241.0% year-over-year from N/an in Q3 2020, and down 36.98% quarter-over-quarter from 39517.77% in Q2 2021.
Corbus Pharmaceuticals Holdings (CRBP) EBT Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBT Margin history runs 7 years deep, the most recent figure standing at 54130.64% for Q3 2021.
- In Q3 2021, EBT Margin fell 4859241.0% year-over-year to 54130.64%; the TTM figure through Jun 2022 stood at 98105.61% (down 9287666.0% YoY), while the FY2021 annual figure was 14912.83%, down 1096770.0% from the prior year.
- EBT Margin for Q3 2021 stood at 54130.64%, down from 39517.77% in the prior quarter.
- The five-year high for EBT Margin was 95.2% in Q4 2019, with the low at 54130.64% in Q3 2021.
- The 5-year median for EBT Margin is 3479.77% (2018), against an average of 9150.95%.
- The sharpest annual moves came in 2018 and 2021: EBT Margin jumped 571782 bps in 2018, then slumped 4859241 bps in 2021.
- Corbus Pharmaceuticals Holdings' EBT Margin stood at 4639.19% in 2017, then soared by 80 bps to 913.05% in 2018, then soared by 110 bps to 95.2% in 2019, then sank by 1411 bps to 1248.06% in 2020, then slumped by 4237 bps to 54130.64% in 2021.
- Business Quant data shows CRBP's EBT Margin at 54130.64% in Q3 2021, 39517.77% in Q2 2021, and 7988.91% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -54,130.64% |
| Jun 30, 2021 | -39,517.77% |
| Mar 31, 2021 | -7,988.91% |
| Dec 31, 2020 | -1,248.06% |
| Sep 30, 2020 | -5,538.24% |
| Jun 30, 2020 | -24,210.21% |
| Mar 31, 2020 | -3,316.84% |
| Dec 31, 2019 | 95.20% |
| Sep 30, 2019 | -1,784.14% |
| Jun 30, 2019 | -58.77% |
| Mar 31, 2019 | -2,297.54% |
| Dec 31, 2018 | -913.05% |
| Sep 30, 2018 | -4,340.91% |
| Jun 30, 2018 | -3,642.70% |
| Mar 31, 2018 | -1,248.55% |
| Sep 30, 2017 | -4,639.19% |
| Jun 30, 2017 | -9,360.53% |
| Mar 31, 2017 | -576.18% |
| Sep 30, 2016 | -4,744.73% |
| Jun 30, 2016 | -3,418.85% |